"Changes in soluble CD163 indicate monocyte involvement in cognitive deficits in Parkinson's disease"

Sara K. Nissen¹, Sara A. Ferreira¹, Claudia Schulte², Kalpana Shrivastava¹, Dorle Hennig³, 3 Jonas Graversen³, Walter Maetzler⁴, Daniela Berg^{2,4}, Anne Panhelainen⁵, Holger J. Møller⁶, 4 Kathrin Brockmann², Marina Romero-Ramos^{1#} 5 6 1. DANDRITE & Department of Biomedicine, Aarhus University, Aarhus, Denmark. 7 Center of Neurology, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research 2. 8 & German Center for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany. 9 3. Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark 10 4. Department of Neurology, Christian-Albrechts University, Kiel, Germany. 11 5. Institute of Biotechnology, University of Helsinki, Helsinki, Finland. 12 6. Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark

Corresponding author: Marina Romero-Ramos, Dept. of Biomedicine, Aarhus University, Høegh Guldbergsgade 10, DK-8000C Aarhus, Denmark. Phone: +45 87167854. E-mail:mrr@biomed.au.dk

15

16 **ABSTRACT:**

17

18 Parkinson's disease is a neurodegenerative disorder with a significant immune component. Numerous studies have 19 reported alterations on immune biomarkers in CSF and serum that associate with symptoms in PD patients. 20 However, it is unclear, which specific immune cells are responsible for the changes in those biomarkers; since 21 most of these cytokines or chemokines, can be produced by a variety of immune cells, or even neurons or glia cells 22 in the brain. Here, we investigate a monocyte/macrophage-specific biomarker: sCD163, the soluble form of the 23 receptor CD163. Our data from tow cohorts show that the CSF-sCD163 increases as the disease progresses, 24 together with a correlated increase in PD-specific as well as neurodegeneration-associated disease biomarkers: 25 alpha-synuclein, tau, and phosphorylated-Tau. Moreover, CSF-sCD163 levels were inversely correlated to the 26 cognitive scores MMSE and MOCA, with higher sCD163 indicating lower cognitive capacity. sCD163 was also 27 increased in serum, although only in female PD patients, suggesting a gender distinctive monocyte-related immune 28 response. CSF-sCD163 also correlated with molecules associated with endothelial cells, tissue infiltration, and 29 activation of B cells and T cells in the PD patients. This suggests activation of both the adaptive and the innate 30 immune system along with recruitment of lymphocytes and monocytes to sites of inflammation in the brain. In 31 serum, sCD163 was associated with pro-inflammatory cytokines and acute phase proteins, suggesting a relation 32 to chronic systemic inflammation. Interestingly, our in vitro study suggests that sCD163 might enhance alpha-33 synuclein uptake by myeloid cells without direct binding, thus participating in the clearance of alpha-synuclein. 34 Accordingly, our data supports sCD163 as a potential cognition-related biomarker in PD and corroborates a role 35 for monocytes both in peripheral and brain immune responses that could have direct consequences in the handling 36 of alpha-synuclein.

37 Key Words: monocytes, sCD163, biomarkers, cognition, alpha-synuclein, Parkinson

- 38
- 39
- 40

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 INTRODUCTION:

2

3 Parkinson's disease (PD) is the second most common neurodegenerative disorder and it is characterized by 4 intraneuronal aggregations of alpha-synuclein (α -syn) and a significant dopaminergic neuronal cell death in the 5 substantia nigra. Besides these neuronal events, the disease also involves an early and chronic immune activation 6 related to disease progression [78]. Indeed, post mortem analysis of PD brains has shown microgliosis, i.e. changes 7 in microglia number, morphology, and expression pattern in several areas of the brain [31]. This is also observed 8 using PET imaging in patients [20]. The immune response does not seem related to the occurrence of neuronal cell 9 death, but rather to the presence of α -syn pathology and the neurodegenerative process ongoing in each brain area. 10 α-syn seems to play a central role in the immune activation by acting as a damage-associated molecular pattern 11 (DAMP), initiating a sterile response, which contributes further to the disease progression [16].

12

13 The immune response in PD is not limited to the brain, but involves both innate and adaptive immune cells in the 14 peripheral immune system. Accordingly, we and others have previously shown changes in the monocytic 15 population in PD patients with an increased proliferative and phagocytic capacity, an abnormal response to 16 immune stimuli [57, 86], as well as their altered transcriptome compared to healthy individuals [71]. Moreover, 17 changes in T cells have also been described in PD patients; such as alterations in the different subpopulations with 18 an inclination towards pro-inflammatory Th1 and Th17 phenotypes [41, 77]. These peripheral alterations will also 19 affect the brain, since we and others have shown brain-infiltration by both T cells and monocytes in PD patients 20 and in animal models [6, 25, 79]. Indeed, the involvement of the (peripheral) immune system in PD is also 21 confirmed by the changes in cytokines and chemokines reported both in serum and CSF. A recent meta-analysis 22 reported that PD patients' blood showed increased levels of IL-1β, TNF-α, IL-6, and IL-10, while in CSF, IL-1β, 23 IL-6, TGF- β 1 and CRP were increased, together with a decrease in interferon- γ (IFN- γ) [36]. This suggests a 24 complex immune response, with both pro-inflammatory and anti-inflammatory chronic processes occurring during 25 disease in brain and periphery. In addition, multiple studies have shown that these biomarkers correlated with the 26 symptomatology in PD, further supporting a malfunction of the immune system in the disease [78].

27

28 It was previously reported that PD-related immune biomarkers can be produced by a number of different cell types 29 (monocytes and/or lymphocytes, endothelial cells, and even glia and neurons), [87], therefore, these biomarkers 30 cannot truly reveal the unique intervention of each of the cell populations involved in the immune response. 31 Remarkably, this is not the case with the soluble CD163 (sCD163), a protein produced exclusively by the monocyte 32 cell lineage (monocytes, macrophages, and dendritic cells (DCs)), but not by lymphocytes, neurons [15, 63] or 33 microglia, which was confirmed in a recent study by single-cell RNA sequencing in mice [35]. In the brain, CD163 34 is found in meningeal macrophages and perivascular macrophages. sCD163 has been used as biomarker of diverse 35 diseases with an inflammatory component [15]. sCD163 is constitutively produced by cleavage of the extracellular

36 portion of CD163, the endocytic receptor for hemoglobin-haptoglobin complexes, and can be measured in

- 37 biological fluids (serum and CSF) [55]. The receptor's ectodomain is cleaved by the metalloproteinase ADAM17
- 38 [14], which also produces TNF- α and the soluble forms of other immune-related molecules and has been related

1 to Alzheimer [26]. This enzyme is activated by the TLR-4 cascade/signaling, and other stimuli including oxidative 2 stress and cell activation [49]. Therefore, an increased level of sCD163 in biofluids can relate to macrophage 3 activation and correlates with the degree of inflammation in different diseases with a relevant immune component 4 [15]. In the present study, we seek to analyze the levels of sCD163 in blood and CSF from PD patients at different 5 disease stages in order to evaluate the monocytic involvement in the disease progression. To do so, we correlated 6 this biomarker with well-accepted PD biomarkers and clinical symptoms, as well as screened for other potential 7 biomarkers. Our data support an important role for the monocytes in PD, particularly related to cognitive-decline, 8 and reveal sCD163 as a promising PD biomarker.

9

10 MATERIALS AND METHODS:

11

12 Participants

PD patients have been recruited from the outpatient clinic and/or ward for Parkinson's disease at the University Hospital of Tuebingen. Spouses of patients and volunteers recruited by newspaper advertisements were assessed to have no neurodegenerative disease and served as control participants.

16

17 Clinical Investigations

- 18 All participants were examined by a neurologist specialized in movement disorders. Diagnosis of PD was made 19 according to the UK Brain Bank Society Criteria [45]. None of the included patients showed "red flags" indicating 20 an atypical parkinsonism over time. PD patients were assessed in the dopaminergic ON state. We assessed severity 21 of motor symptoms using part III of the MDS Unified Parkinson's disease Rating Scale (MDS-UPDRS III) [22]. 22 Disease stage was categorized by the modified Hoehn and Yahr Scale (H&Y) [21]. Cognitive function was tested 23 using the Montreal Cognitive Assessment (MoCA) [29] and/or the Mini Mental Status Examination (MMSE) [17]. 24 Since the MoCA was available only from 2009 on, all previously obtained MMSE scores were converted into 25 MoCA equivalent scores according to published algorithm [4]. Cognitive impairment was defined according to 26 the DSM-IV (2003-2013) or DSM-V (2013-2019) criteria and/or MoCA ≤25 as reported by Hoops et al. (point of 27 maximum combined sensitivity and specificity) [29]. Mood disturbances were assessed using Beck's Depression 28 Inventory II (BDI II) [3]
- 29

30 Collection of CSF and serum Samples

31 Spinal tap for CSF collection along with serum collection were performed between 9.00 AM and 1.00 PM. Samples

- 32 were directly taken from the bedside and centrifuged within 60 min after collection and frozen at -80°C within 90
- 33 min after collection. Samples with abnormal routine CSF diagnostics (white blood cell count >6 cells/µl,
- 34 Immunoglobulin Subtype G (IgG) index > 0.7) were excluded.

1

2 Ethical statement

3 The study was approved by the local ethics committee (480/2015BO2), with all participants providing informed4 consent.

5

6 Cohorts

The study was conducted on two cross-sectional idiopathic PD cohorts including controls (overview in **Fig. 1**). *Cohort #1:* Serum and CSF samples from 109 PD patients (early [\leq 5y from diagnosis] and late [\geq 5y from diagnosis]) and 44 controls (**Table 1**). *Cohort #2:* Serum and CSF samples from 106 PD patients (early and late) and 16 controls (**Table 2**). Twenty-eight individuals from cohort #1 were also part of cohort #2, however, other aliquots of the biomaterials were used. Furthermore, 26 additional serum control samples remaining from cohort #1 were included in the 40-plex mesoscale analysis for cohort #2 (**Suppl. Table 1**).

13

14 Neuronal markers in CSF

CSF levels of total human Tau (h-Tau) and phosphorylated Tau (p-Tau) (phosphorylation of Tau at threonine 181)
 were measured using commercially available ELISA kit (Innotest; Innogenetics, Ghent, Belgium). Total α-syn
 values were analyzed at Analytic Jena, using an ELISA (Mono-Kit, Analytic Jena Roboscreen GmbH, Leipzig,

18 Germany). Abeta₁₋₄₂ (Abeta42) in CSF was measured with a commercially available ELISA kit (Innotest®;

19 Fujirebio Germany GmbH, Hannover, Germany). All measurements were performed by board-certified laboratory

- 20 technicians who were blinded to clinical data.
- 20 technicians who were blinded to clinical
- 21

22 sCD163 measurements

Total sCD163 was measured in serum and in CSF using an in-house ELISA as previously described [53, 57]. The % of intrathecally produced sCD163 was calculated as follows: The CSF concentration of sCD163 derived from the circulation was calculated based on the CSF/serum albumin quotient: serum sCD163 x (CSF albumin/serum albumin concentration). The sCD163 produced intrathecally was calculated by subtracting the above value from the absolute CSF concentration[18].

28

29 40-plex mesoscale

30 MSD MULTI-SPOT Assay System (Mesoscale) was used to measure 40 different soluble molecules in serum and 31 CSF on cohort #2 (and additional serum controls from cohort #1, see Fig. 1 and Table 2), using Human Biomarker 32 40-plex kit following manufacturer's best practices instructions. All samples were used after a single freezing 33 cycle, except for the additional healthy serum controls from cohort #1 (Fig. 1/Table 2), which had been thawed 34 once before, and were only included in assays (Suppl. Table 1) where we had validated that an additional 35 freeze/thawing-cycle did not affect the measurements. MSD plates were run on MESO QuickPlex SQ120 (MSD) 36 with MSD Discovery Workbench software. For each plate and panel, the upper and lower limit of quantification 37 (ULOQ & LLOQ) or detection (ULOD & LLOD) were noted. No measurements were >ULOD, assays with

samples below LLOD were excluded (Suppl. Table 1), and ULOQ or LLOQ are shown on relevant graphs. For
 more details, see supplementary information.

3

4 In vitro analysis of α-synuclein uptake and binding

5 THP-1 and BV-2 cells were grown in 75cm² flasks in culture media consisting of 2mM L-Glutamine, 10% FBS 6 in RPMI 1640. For the THP-1 experiment, 80.000 cells per well were plated onto 24-well plates and treated with 7 100nM PMA (Phorbol myristate acetate, InvivoGen, France) for 72h for macrophage-differentiation and 8 attachment. For the BV-2 experiment, 70,000 cells per well were plated onto 24-well plates and cultured for 24 h

- 9 before α -syn treatment.
- 10 The plates with differentiated THP-1 macrophage-like cells or BV-2 murine microglia cells were placed on ice for
- 11 15min before adding ¹²⁵I- α -syn fibrils (50 ng/ml, see supplementary info for details) onto the cells, either with 12 PBS as vehicle control, sCD163 (5µg/ml, see supplementary info for details), or added after 30min of pre-treatment
- PBS as vehicle control, sCD163 (5 μ g/ml, see supplementary info for details), or added after 30min of pre-treatment with sCD163 (5 μ g/ml) at 37°C. To evaluate α -syn internalization, the plates were placed into a 37°C water bath
- 14 to allow uptake of the fibrils for 5, 15 or 45min, after which the plates were returned on ice. The cells were washed
- 15 with 500µl ice-cold PBS twice for 5min and next, to remove the bound preformed fibrils from the cell surface,
- 16 they were washed with 500µl acid wash (0.2M acetic acid, 0.5M NaCl, pH 2.8) for 5min. Afterwards, the cells
- 17 were lysed by adding 500µl 1M NaOH to each well and collected into appropriate counting vials. Radioactive
- 18 counts per minute (CPM) were counted in the Wizard 3" 1480 Automatic Gamma counter (Wallac/LKB). For
- 19 assessment of surface binding, the plates were kept on ice for 1h, washed with 500µl ice-cold PBS twice for 5min,
- 20 lysed, and collected with 500µl of 1M NaOH into vials for counting. Values were normalized to α-syn average
- 21 counts. Results are given in percentage of internalization/surface binding.
- 22

23 Microscale Thermophoresis for assessment of sCD163-a-synuclein interaction

24 Evaluation of protein binding through the Microscale Thermophoresis technique was performed by labeling human 25 His-Tag sCD163 (target protein) with RED-tris-NTA 647 2nd generation fluorescent dye (excitation:650nm; 26 emission: 670nm) using the Monolith His-Tag labeling Kit RED-tris-NTA 2nd generation (NanoTemper 27 Technologies, Cat Nr:L018). Fluorescently labeled sCD163 was used at a concentration of 60nM. For binding 28 evaluation, a 16x dilution series (1:1) was performed on 20μM human α-syn (ligand) reaching 0.61nM 29 concentration. The MST buffer used contained 10mM HEPES, 150mM NaCl, 0.05% Tween, 0.1%BSA, and 3 30 different concentrations of CaCl2 for testing calcium-dependent binding. Fluorescent target and ligand were mixed 31 (1:1) and samples were loaded in Monolith NT.115 Premium Capillaries (NanoTemper Technologies, Cat Nr: 32 K025) and measured in the Monolith NT.115 instrument (100% LED/excitation power and medium MST power). 33 The experiment was repeated three times for each calcium condition. Dose-response values were evaluated in the

- 34 MO Affinity analysis software and compared between conditions.
- 35

36 Statistical analyses

37 GraphPad Prism V7, JMP 14, and STATA v15 IC were used for statistical analyses and data plotting. For gender-

38 and group differences as well as correlations, the use of parametric vs. non-parametric tests were determined by

- 1 testing Gaussian normality distribution with a D'Agostino-Pearson omnibus normality test, followed by unpaired
- 2 t test (or Mann-Whitney), 1-way ANOVA (or Kruskal-Wallis test) with Tukey's (or Dunn's) multiple comparisons
- 3 test, and Pearson (or Spearman) correlation coefficient calculations as appropriate.
- 4 Simple linear and multiple linear regression were calculated to predict clinical scores or biomarkers for PD patients
- 5 based on CSF-sCD163 values alone or adjusted for age and/or disease duration. For the analysis of correlations
- 6 between sCD163 and the Multiplex markers, Bonferroni corrections in the p-values were used.
- 7 In cohort #2: Odds ratios of single CSF or serum biomarkers effect on PD diagnosis (PD vs. HC) were estimated
- 8 using logistic regression; main effect of PD progression (UPDRS III, MoCA, Mini Mental (MMSE (O)), or MMSE
- 9 original plus converted from MoCA (MMSE O+C)) were calculated using linear regression. The main effect of
- 10 single biomarkers was plotted as forest plots. For both PD diagnosis and PD progression, prediction of combined
- 11 effect of biomarkers calculated using three stepwise forward prediction models: m1) probability of entry is 0.1,
- 12 probability of removal is 0.2; m2) probability of entry is 0.05, probability of removal is 0.1; and m3) probability
- 13 of entry is 0.1, probability of removal is 0.2, sCD163 forced to be included. The three models were compared
- 14 using AIC and BIC (probabilistic model selection criterion). For the three final models on PD diagnosis, a
- 15 classification table was calculated and Hosmer-Lemeshow goodness of fit was conducted (χ^2). For each model of
- 16 PD progression (UPDRS III, MoCA, Mini Mental, or MMSE O+C), the adjusted R squares were calculated and
- 17 the observed scores were graphed against their fitted value.
- 18 For in vitro experiments, the use of a Two-way ANOVA was determined after testing Gaussian normality
- 19 distribution with a Shapiro-Wilk normality test followed by Tukey's multiple comparisons test.
- 20

21 **RESULTS**

22

23 Screening of sCD163 as a (cognitive) progression biomarker (cohort #1)

24 Our and others' previous studies in rodents [25, 79] and humans [56] suggest that CD163⁺ cell populations might 25 have a relevant role in PD. In addition, multiple studies have shown that sCD163 can be used as a valuable 26 biomarker on diseases with an important immune component [15]. Thus, we aimed to investigate the potential of 27 sCD163 as a CSF and serum biomarker for PD diagnosis and progression in a cohort of 109 PD patients and 44 28 healthy controls (HCs) with similar gender and age distribution (cohort #1) (Fig. 1; Table 1). Our analysis shows 29 that CSF-sCD163 was elevated in late PD (Fig. 2A), with no gender discrepancies. In serum we observed a gender 30 and treatment effect in the levels of sCD163 (not shown), thus we separated the data by gender and to eliminate 31 the treatment variable we analyzed only treated PD patients samples. The analysis showed that serum sCD163 32 levels were elevated in late female PD patients (vs. early), but not in male PD patients (Fig. 2B). To confirm that 33 the changes in sCD163 in CSF were not a simple leakage from serum we calculated the amount of sCD163 34 intrathecally produced and that derived from serum, using as refence the ratio albumin CSF/serum (when available) 35 as previously described [18]. We did not see any significant difference in the amount sCD163 in CSF of serum 36 origin (not shown); however, the sCD163 produced intrathecally was higher in late PD (0.0739 ± 0.037) vs. early

PD (0.0601±0.019, p=0.03), thus confirming that the increase observed was due to elevated CD163 shedding
 within the brain.

3 Interestingly, for the PD patients, sCD163 in CSF correlated positively with levels of well-characterized 4 neurodegenerative markers (α -syn, h-Tau, and p-Tau) in CSF even after compensating for age and disease duration 5 (Fig. 2C-E, Suppl. Table 2). Since these biomarkers have been previously related to symptomatology in PD, we 6 analyzed putative correlations between sCD163 and clinical scores. Remarkably, CSF-sCD163 was negatively 7 correlated with cognitive progression measured by both the MoCA and the MMSE scores in the PD patients (also 8 to some degree when separated by gender or early/late disease status) (Fig. 2F-H, Table 1, Suppl. Table 3). 9 Similarly, serum-sCD163 did also correlate positively with the neuronal markers from CSF (α -syn, h-Tau (only 10 trending), and p-Tau; Fig. 2I-K), even after compensation for covariance, however, sCD163 in serum did not

correlate with the cognitive scores (data not shown). Neither serum- nor CSF-sCD163 did correlate with the H&Y,

12 13

11

14 Confirmation of sCD163 as a disease biomarker (cohort #2)

UPDRS III, or LEDD after compensating for co-variables (data not shown).

- 15 Based on the central finding of sCD163 increasing during disease and the correlation between CSF-sCD163 and
- 16 cognitive PD problems, we aimed to confirm these findings in a second cohort (#2) (Fig. 1, Table 2). Indeed, we
- 17 corroborated an increase of CSF-sCD163 in late PD in the cohort #2 (Fig. 3A). Moreover, the estimated amount
- 18 of sCD163 in CSF with serum origin was similar across groups (not shown), while the sCD163 intrathecally
- produced was increased in late PD (0.109 ± 0.047) vs. early PD (0.071 ± 0.018 , p=0.004) and vs. healthy control
- 20 $(0.074 \pm 0.023 \text{ p}=0.02)$, suggesting an increased sCD163 production in brain. We confirmed as well, the gender
- 21 difference observed for serum-sCD163 in the first cohort, with an increase in serum-sCD163 for females only
- 22 (analyzing only treated PD patients, **Fig. 3B**).
- 23 In agreement with observations from cohort #1, correlations of CSF-sCD163 with the PD-related CSF markers (α-
- syn, h-Tau, and p-Tau) were found as well in cohort #2 (Fig. 3C-E). Linear regressions between CSF-sCD163
- 25 and these markers remained significant even when age of visit was accounted for (not shown). Moreover, in cohort
- 26 #2 sCD163 in CSF was significantly correlated to levels of Abeta42 (Fig.3F). The association between serum-
- 27 sCD163 and CSF biomarkers, showed also similar pattern, with significant correlation to α -syn and p-Tau, a trend
- 28 with h-Tau and no correlation with Abeta42 (Fig. 3J-M).
- 29 Of importance, this was also true for cognitive scores, which decreased while sCD163 increased (Fig. 3G-I, Suppl.
- 30 Table 4). Since we corroborated the negative correlations between cognitive scores and CSF-sCD163, we
- 31 examined whether such correlation would persist when adjusted for covariance by comparing simple linear and
- 32 multiple linear regressions (Suppl. Table 5&6). Importantly, when adjusting CSF-sCD163 for age at PD onset or
- 33 time with PD diagnosis, the slopes were still significantly different from zero (thus negatively correlated) for both
- 34 scores (MoCA or MMSE O+C). As expected, age was influencing the cognition scores and sCD163, however,
- 35 CSF-sCD163 concentration still associated significantly with the cognitive decline. In fact, a significant p value
- 36 remained for CSF-sCD163 even when adjusting for age at visit alone, or in combination with age at onset or
- 37 disease duration for the MMSE O+C score (with most available data points). Thus, an increase in CD163 of
- 38 = 0.1 mg/L corresponded to a decline of ~3 in the MMSE O+C score, however, when adjusting for both age at visit

- 1 and disease duration, the decline would only be expected to be ~ 1.8 (Suppl. Table 5). This demonstrates that
- 2 CD163 associates with cognitive decline even when patient age and disease duration are considered.
- 3

4 Screening for other CSF biomarkers (cohort #2)

5 sCD163 is considered a marker for monocyte/macrophage immune activation [51], thus we decided to analyze 40 6 biomarkers related to the immune system and angiogenesis/vascular permeability using validated (V-plex) 7 immunoassays (mesoscale, MSD) in both serum and CSF. Only assays with less than three measurements below 8 LLOD were considered reliable and further analyzed (Suppl. Table 1). In CSF, we observed that out of the 16 9 reliable assays, 11 biomarkers showed PD-related changes (Fig. 4). Vascular cell adhesion protein 1 (VCAM-1; 10 CD106), Intercellular Adhesion Molecule 1 (ICAM-1; CD54), interleukin (IL)-8, serum amyloid A protein (SAA) 11 (an acute phase protein), and placenta growth factor (PIGF) were all increased in PD patients (Fig. 4A-D; F). 12 Additionally, another acute phase protein: The C-reactive protein (CRP) also showed a clear trend to increase in 13 PD patients (p=0.059, Fig. 4E). 14 Interestingly, some of the biomarkers assayed showed a progressive change during PD: IL-15 and Vascular 15 endothelial growth factor (VEGF)-D were increased in late PD patients compared to healthy controls, but also

16 when compared to early PD (Fig. 4G-H). Additionally, other markers were different among patients receiving L-

- 17 DOPA and those that were non-treated: Monocyte chemoattractant protein-1 (MCP-1; CCL2) (only in male 18
- patients) and macrophage inflammatory protein-1β (MIP-1β; CCL4) levels showed a decreased in treated (T) vs. 19 untreated (UT) PD patients (Fig.4I-J). An opposite trend was observed for Fms Related Tyrosine Kinase 1 (FLT1;
- 20 VEGFR1) (Fig.4K). No PD-related changes were observed in the remaining four CSF biomarkers with values
- 21
- >LLOD (Suppl. Fig. 1). In sum, our data demonstrate increased monocyte-driven inflammation and indicate
- 22 increased blood-brain-barrier (BBB) permeability in PD patients.
- 23

24 Screening for other serum biomarkers (cohort #2)

25 We next aimed to investigate the same biomarker panel in serum samples from cohort #2. Surprisingly, with 27 26 reliably measured biomarkers, only nine showed PD-related changes (Fig. 5). However, in agreement with our 27 CSF observations, VCAM-1 was significantly increased in PD patient's serum (Fig. 5A), while VEGF-C C was 28 significantly decreased (Fig. 5B). A trend to increase during PD was also found for ICAM-1, CRP, IL-12/IL-29 23p40, and IL-6 (in females) (Fig. 5C-F). As showed in CSF, some disease-progression changes were also

- 30 observed: IL-15 and VEGF-D were both increased in late PD serum samples compared to early PD patients (Fig.
- 31 5G-H). No PD-related changes were observed in the remaining 18 serum biomarkers with values >LLOD (Suppl.
- 32 Fig. 2).

33

34 Correlation between multiple CSF and serum biomarkers with sCD163 (cohort #2)

35 To investigate any association with the newly discovered sCD163 PD biomarker and the other immune molecules

36 with PD-related changes, we investigated the presence of correlations of sCD163 with the 40-plex in CSF (Fig.

37 6A-B) and serum (Fig. 6C-D). We also decided to explore the associations to the biomarker panel separated by

1 gender in their serum samples due to our *a priori* finding of sCD163 being gender-dependent in serum (Suppl.

- 2 **Fig. 3**).
- 3 Our analysis showed that CSF-sCD163 was positively correlated with several biomarkers in CSF; both when
- 4 examining all PD patients and by separating them by early- and late disease status. The strongest significant
- 5 correlations for CSF-sCD163 observed at all disease stages were those seen among IL-15 (r 0.72, all PD), ICAM-
- 6 1 (r 0.63, all PD), VCAM-1 (r 0.61, all PD), and Flt-1 (r 0.51, all PD). Several chemokines were also strongly
- 7 correlated with CSF-sCD163 in late PD: IP-10 (CXCL10, r 0.52), MIP-1B (CCL4, r 0.51), and MCP-1 (CCL2, r
- 8 0.44) (**Fig. 6B**).
- 9 In serum, the sCD163 correlations were weaker and fewer (Fig. 6D): serum-sCD163 was correlated with IL-6 (at
- 10 all disease stages; best fit with all PD, r 0.39), ICAM-1 (r 0.34, all PD), and SAA (r 0.35, all PD). Other biomarkers
- 11 were correlated to serum-sCD163 especially at late PD such as TNF-α (r 0.55), IL-12/IL-23p (r 0.47), VCAM-1
- 12 (r 0.57), and CRP (r 0.41). Remarkably, the strong correlation between sCD163 and IL-15 observed in CSF was
- 13 absent in serum. Overall, our results demonstrate that the monocyte/macrophage-specific serum and CSF
- 14 biomarker, sCD163, associates not only to cognitive decline but also to well-described inflammation markers.
- 15

16 Cognition related biomarkers (cohort #2)

- 17 Accordingly, we aimed to assess whether our previously described association with sCD163 and cognition was 18 unique for this immune biomarker, thus we investigated correlations between MMSE O+C and all other 19 investigated reliable biomarkers. Besides sCD163, only IL-15 of all the investigated CSF biomarkers had a strong 20 negative correlation (in all PD stages) with MMSE (O+C) and a significant linear regression (Fig. 7A-C), as 21 expected since sCD163 and IL-15 in CSF, were strongly correlated (Fig. 7E). Interestingly, IL-15 was the only 22 serum biomarker found to negatively correlate and have a significant linear regression with MMSE (O+C) (Fig. 23 7D). Other CSF markers also showed a significant negative correlation and a significant linear regression (not 24 shown) with cognitive scores MMSE (O+C), although only in late PD, such as IL-7 (r -0.48) CCL2 (r -0.33), IL-25 8 (r -0.32), and PIGF (r -0.31). No biomarker was found to correlate with the motor deficiency/impairment, except 26 for serum-VEGF-A, which had a significant negative correlation and significant linear regression with UPDRS III 27 scores (Fig. 7F). Critically, sCD163 shows unique qualities being cell type-specific and having associations with 28 BBB leakage, immune activation, and cognition.
- 29

30 Single biomarkers as a predictor of progression (cohort # 2)

In order to investigate the serum and CSF biomarkers effect on PD diagnosis (PD vs. HC) and PD progression (UPDRS III, MoCA, MMSE, and MMSE original (O) plus converted from MoCA (MMSE O+C)) we used logistic and linear regression to estimate the odds ratio and regression slopes, respectively. The main effect on PD diagnosis and progression of the single (re-scaled) biomarkers in serum and CSF were plotted as forest plots (**Suppl. Fig. 4-**5). For serum biomarkers ability to predict PD diagnosis, VCAM-1, IL-10, and sCD163 had significant p values; for the ability to predict progression by UPDRS III, p values were significant for VEGF-A and Flt-1; progression by MoCA, p values were significant for SAA, PIGF, IL-8, IL-15, and CRP; progression by MMSE O, p values

38 were significant for SAA, IL-8, ICAM-1, Eotaxin-3, and CRP; progression by MMSE O+C was the same as for

1 MMSE O plus IL-15 (Suppl. Fig. 4). For CSF biomarkers ability to predict PD diagnosis, VEGF-D, IL-8, α-syn ,

- 2 and sCD163 had significant p values; for the ability to predict progression by UPDRS III, none of the measured
- 3 CSF biomarkers stood out; by MoCA, VCAM-1, SAA, PIGF, IL-7, IL-15, p-Tau, h-Tau, α-syn, and sCD163 had
- 4 significant p values; by MMSE O, SAA, IL-6, IL-15, and sCD163 had significant p values; For MMSE O+C,
- 5 VCAM-1, SAA, MIP-1B, IL-7, IL-15, and sCD163 had significant p values (Suppl. Fig. 5). Thus, both serum-
- 6 and CSF-sCD163 appear to be good predictors for PD and cognitive decline.
- 7

8 sCD163, a predictor of progression in various statistical models (cohort# 2)

- 9 With sCD163's apparent ability to singlehanded predict PD diagnosis (both in serum and in CSF) and cognition 10 by all cognitive scores in CSF, our data supported sCD163 as a valid biomarker to predict both PD diagnosis and 11 progression with respect to cognition. However, sCD163 is also dysregulated in other diseases with an 12 inflammatory component, so a combined biomarker panel might be necessary to distinguish (risk of) PD from 13 other diagnoses, or progression from general aging. Therefore, we next aimed to model a combination of biomarker 14 panels to follow PD diagnosis and progression (or possible changes after therapeutic intervention) using three 15 variants of stepwise forward modeling with variable probability for biomarkers to enter the model; and with 16 sCD163 being forced to be included in model (m) 3 (Suppl. Table 7&8). For each prediction score, the best model 17 of serum and CSF biomarkers were selected and plotted with goodness-of-fit (Fig. 8&9). For serum, m1 was the 18 strongest models to predict UPDRS III (Fig. 8A), MMSE O (Fig. 8C), and MMSE O+C (Fig. 8D), whereas the 19 m3 including serum-sCD163 (with IL-15, CRP, MCP-1 PIGF, and IL-7) were best fitted to predict MoCA and 20 overall had the highest R square (0.29) (Fig. 8B). Likewise for CSF, m3 for the MoCA including CSF-sCD163 21 (with p-Tau, IL-7, and IL-8) had the highest R square (0.32) (Fig. 9B), whereas none of the calculated CSF models 22 seemed to fit for UPDRS III, MMSE O, or MMSE O+C (R square all <0.1)(Fig. 9A;C;D). Taken together, sCD163
- 23 in both serum and CSF holds a good potential as a single biomarker or an essential part of a biomarker panel to
- 24 predict PD progression (and diagnosis) by measurement of biofluids.
- 25

26 sCD163 as a potentiator of α-synuclein fibril internalization in myeloid cells

Since our data showed a progressive increase of sCD163 during disease and the levels of the protein were positively correlated to α -syn in CSF, we sought to analyze any possible interaction by a direct binding using Microscale Thermophoresis. As CD163 binding to hemoglobin-haptoglobin complexes has been shown to be calcium-dependent [47], we evaluated three different calcium concentrations to test sCD163- α -syn interaction. No

- 31 significant signs of co-interaction were observed in any of the conditions assayed (Suppl. Fig. 6).
- 32 We then speculated whether sCD163 had any effect on the myeloid response to α -syn. Since one of the relevant
- 33 functions of myeloid cells in PD is the clearance of α -syn, we aimed to evaluate the effect of sCD163 on α -syn
- 34 uptake. To do so, we chose two cell lines: Human monocytic THP-1 cells differentiated to a macrophage-like stage
- 35 and mouse microglia BV-2 cells, in order to obtain information from the two main myeloid cells involved in PD.
- 36 Cells were incubated with radiolabeled α -syn fibrils alone or with sCD163 as co-or pre-treatment (30min) (Fig.
- 37 **10A**). After 5min, THP-1 cells showed increased α -syn internalization when co-treated with sCD163 (+15%) or
- 38 pre-treated with sCD163 (+10%) compared to α -syn alone (Fig. 10B). While in the BV-2 cells, the uptake of α -

syn increased only when the cells were pre-treated with sCD163: after $5\min(+53\%)$ and $15\min, (+35\%)$ compared to α -syn alone. Interestingly, in the BV-2 cells with the co-incubation approach, α -syn uptake was only increased after $45\min(+15\%)$, with no changes at earlier time-points (**Fig. 10C**). This might suggest that the effect on microglia could require certain intracellular machinery, hence the delay, versus the more rapid effect in the monocytes. However, we cannot discard the possibility that the differences are only due to species disparities. Taken together, these results indicate that CD163 has an α -syn uptake-related function, which might have consequences in the PD-progression.

8

9 **DISCUSSION**

10

11 Genetic data suggest that the inflammatory component in PD is mainly driven by the myeloid compartment of the 12 immune system, which includes not only microglia in the brain, but also monocyte-derived cells [65]. Moreover, 13 recent data from gene expression analysis on monocytes show that PD-associated genetic risk factors influence 14 innate immune mechanisms [44]. Numerous studies have reported alterations on immune biomarkers in CSF and 15 serum that associate with symptoms in PD patients [36, 64]. However, it is unclear, which immune cells are 16 specifically responsible for the changes in those biomarkers; since most of these cytokines or chemokines can be 17 produced by a variety of immune cells, or even neurons or glia in the brain. Here, we investigate a 18 monocyte/macrophage-specific biomarker: sCD163, the soluble form of the receptor CD163 [15]. Our data shows 19 that the CSF-sCD163 increases as PD progresses together with a parallel increase in well-accepted disease 20 biomarkers: α-syn, h-Tau, and p-Tau. Moreover, levels of sCD163 were inversely correlated to cognitive scores 21 MMSE and MOCA, with higher sCD163 indicating lower cognitive capacity. sCD163 was also increased in serum, 22 although only in female PD patients, suggesting a gender distinctive response of the monocytic immune system. 23 These changes in sCD163 levels are indicative of a monocytic activation occurring in parallel to variations in 24 several cytokines, chemokines, and angiogenic factors. These changes were different in CSF vs. serum, supporting 25 a distinctive immune profile in the brain and periphery that in turn, correlated mostly with cognitive scores. 26 Statistical analysis confirmed sCD163 as a good predictor of PD and cognitive capacity. Additionally, we describe 27 mathematical models that could be used for addressing PD cognition by MoCA using sCD163 in combination with 28 IL-15, CRP, MCP-1/CCL2, PIGF, and IL-7 in serum; and p-Tau, IL-7, and IL-8 in CSF. Interestingly, our in vitro 29 study, suggest that sCD163 might enhance α -syn uptake by myeloid cells, thus participating in the clearance of α -30 syn. Accordingly, our data supports sCD163 as a potential biomarker in PD and corroborates a role for monocytes 31 both in peripheral and brain immune responses during PD that could have direct consequences in the handling of 32 α-syn. 33 Our analysis of the two PD cohorts showed that sCD163 is increased in biofluids in PD patients. Constitutive 34 shedding of CD163 occurs from healthy human monocytes/macrophages, by the metalloproteinase ADAM17 [14] 35 (which also cleaves VCAM-1 and ICAM-1 [70, 81]). Hence, in our study, we show that these molecules were also

36 increased in PD patients and strongly correlated to sCD163 in both serum and CSF. ADAM17 activity can be

- 37 enhanced by inflammatory signals, such as TLR2/4 activation, therefore, plasma levels of sCD163 can be related
- 38 to monocyte/macrophage activation. Accordingly, increased sCD163 plasma level is associated with the severity

1 of various diseases with an inflammatory component, including multiple sclerosis [15, 75]. Interestingly, two

- 2 diseases genetically related to PD also show increased sCD163: Crohn's syndrome [12] and Gaucher disease [52],
- 3 confirming a shared common myeloid disease mechanism. Although the inflammatory signals that might lead to
- 4 this shedding in PD are yet unknown, it is tempting to speculate that α -syn might contribute to this event. α -syn
- 5 has been shown to act as a DAMP interacting with TLR2 and TLR4 [16]. Furthermore, some studies have shown
- 6 increased levels of these receptors in monocytes from PD patients [23, 86]. A recent article reports increased levels
- 7 of endotoxin in PD patients biofluids, supporting a role for infections in PD, which could account, at least partially,
- 8 for some monocytic (TLR) activation and the shedding of sCD163 [86].
- 9 Our data showed an increase of the sCD163 with time from onset, supporting a progressive increase in the
- 10 involvement of the CD163⁺ cells (monocytic cells) in the disease. This higher sCD163 level in CSF was not a
- 11 simple leakage from serum, since the estimated amount of sCD163 produced intrathecally was indeed elevated in
- 12 PD. The sCD163 found in CSF can be produced by CD163-expressing meningeal, choroid plexus, and perivascular 13
- 14 in brain infiltration of CD163⁺ cells in rodent models of PD [25, 79] and an increase in CD163⁺ cells have been

macrophages, but also by infiltrating macrophages in the brain. Indeed, we and others have observed an increase

- 15 seen in post mortem brains of Alzheimer and PD patients [62]. Therefore, this sCD163 could, at least partially, be
- 16 produced by infiltrating CD163⁺ monocytes and their subsequent local activation. Additionally, our data showed
- 17 that sCD163 in CSF was correlated with markers of angiogenesis and related to monocytes and lymphocytes
- 18 infiltration, such as ICAM-1, VCAM-1, PIGF, and IL-8.
- 19 In contrast to the observations in CSF, sCD163 levels in serum were only significantly changed in female PD
- 20 patients. To our knowledge, only urate has been proposed as a PD biomarker with gender differences [72]. Gender-
- 21 dependent differences in the immune system have long been acknowledged [38]. Similarly, PD has a gender bias
- 22 and immune-related gender differences have already been shown in PD patients [7]. Recent rodent studies also
- 23 suggest that microglia differ between genders, with the female microglia being less pro-inflammatory [84]. The
- 24 gender-specific changes in serum-sCD163 found in the present exploratory study, could be related to the
- 25 differences in PD in female vs. males, with respect to incidence [82], but also to the symptomatic presentation of
- 26 the disease [19]. This is also supported by our previous study that showed a gender-dependent variation in the
- 27 response of PD blood-derived monocytes in vitro [57]. Therefore, the observed gender-differences could be a result
- 28 of gender-specific immune divergences that could have relevant consequences in the risk and presentation of PD
- 29 in each gender.
- 30 We observed that sCD163 was strongly correlated to disease biomarkers α-syn, h-Tau, and p-Tau in CSF. These 31 biomarkers have been associated with PD diagnosis, severity of clinical symptoms and with cognition [30, 34]. 32 Moreover, genetic variants of Tau have been associated with an increased risk of suffering from cognitive 33 symptoms in PD [10]. We found that, although sCD163 did not correlate to motor scores, sCD163 inversely 34 correlated with cognitive scores (MoCA and MMSE), thus suggesting higher monocyte activation in parallel with 35 the development of cognitive problems, supporting a driving role for the immune response in the cognitive 36 component of PD. This is in agreement with imaging studies showing that cognitive scores correlated with 37 increased microglia activation (PK11195 PET) and reduced glucose metabolism in the cortex [13]. Furthermore,
- 38 peripheral immune changes in monocytes seem more relevant in those patients with higher risk to develop

1 cognitive problems [86]. Altogether, our data support a highly relevant role for the monocytes in the cognitive 2 component of PD.

- 3 Our multiplex analysis of soluble markers showed increases in several immune-related markers in PD patients
- 4 without significant gender differences, (except in serum IL-6). Markers for angiogenesis, ICAM-1 and VCAM-1, 5 were consistently found elevated in PD in both biofluids. They are both expressed by cytokine activated endothelial
- 6 cells, astrocytes, and microglia [42, 43]; and are regulators of lymphocytes extravasation across the BBB [74].
- 7 Interestingly, a-syn induces ICAM-1 release from astrocytes [37] and both ICAM-1 and its receptor are increased
- 8 in PD brains and models of PD, related to infiltration of leucocytes [48, 69]. VCAM-1 is increased in serum of PD
- 9 patients with a concomitant decrease of its receptor, VLA4, in T cells and NK cells [28, 61]. Furthermore, PIGF,
- 10 a molecule related to monocyte infiltration in brain, was, similar to another study, increased in PD CSF [32].
- Supporting the role of (lympho-) angiogenesis/BBB-related immune cell-infiltration in PD, VEGF-D progressively 11
- 12 increased during disease in serum and was increased in CSF compared to healthy controls levels [73]. On the 13
- 14 than VEGF-D, although with different affinities and effects [11]. Interestingly, VEGF-D, but not VEGF-C has

contrary, in serum, we found a decrease of the family related VEGF-C, which interacts with the same receptors

- 15 effects in neuronal dendritic arborization and cognition [27]. We also described an increase in IL-8 for PD patients,
- 16 a macrophage-secreted chemokine known to recruit neutrophils and monocytes and promote angiogenesis [39].
- 17 PD patients had also increased IL-15, a cytokine produced by multiple cell types including monocytes, neurons,
- 18 and astrocytes [59]. IL-15 induces BBB permeability [76], DC-differentiation (i.e. antigen-presenting cells, which
- 19 also express CD163); thus, enhancing T cell activation and survival [60]. Further confirming the inflammation,
- 20 we also showed increases in acute phase proteins (SAA and CRP). Increased SAA has been related to PD with
- 21 dementia [24]. Higher CRP levels have been correlated to severe motor impairment, poor psychological well-
- 22 being, and poor sleep in PD patients [67] and it has been suggested not only as a prognostic/risk marker [68] but
- 23 also as a predictor of cognitive decline [50]. Overall, the profile found in the PD patients, was suggestive of an
- 24 active immune response involving both adaptive and innate signals, with a permissive environment for the
- 25 recruitment of immune cells to the brain.
- 26 The levels of sCD163 correlated significantly with some of these soluble markers measured in CSF and serum.
- 27 The strongest association was between sCD163 and IL-15, which accordingly, also correlated to cognition both in
- 28 CSF and in serum. Interestingly, IL-15 receptor is expressed throughout the brain and it has been shown that IL-
- 29 15 has a significant role in mood and memory [59]. sCD163 was also strongly correlated with (soluble) ICAM-1
- 30 and VCAM-1, which as mentioned, are shed by the same enzyme ADAM17. As already reported for rheumatoid
- 31 arthritis [33], we found a significant but weaker association of sCD163, both in CSF and serum, with IL-12/IL-
- 32 23p40, which is produced by antigen-presenting cells upon TLR activation and is involved in Th1/Th17
- 33 differentiation of T cells [46]. Accordingly, IL-12/IL-23p40 has also been found increased/important in PD
- 34 patients and Crohn's disease [7, 85]. In CSF, a significant but weak correlation was seen between sCD163 and
- 35 CCL2, CCL4 as well as CXCL10; all chemokines involved in monocyte recruitment. CCL2 correlates PD
- 36 symptoms [67] and together with CCL4 can be useful for discrimination of clinical subtypes [8, 9]. CXCL10 was
- 37 previously associated with cognition in PD [66]. In serum, however, sCD163 was correlated to pro-inflammatory
- 38 cytokines such as TNF- α and IL-6, as well as to the acute phase proteins CRP and SAA. Therefore, CSF-sCD163
- 39 correlated with immune molecules associated with endothelial cells, infiltration and to activation of B and T cells

in the PD patients, further suggesting activation of both adaptive and innate immune system and to recruitment of
 leucocytes and monocytes to sites of inflammation in the brain. While serum-sCD163 was associated with pro-

- 3 inflammatory and acute phase proteins, suggesting a higher relation to inflammatory events.
- 4 The function of sCD163 is still unclear, but it has been shown to potentiate IL-10 expression in allergen-activated
- 5 PBMCs [5]. In addition, sCD163 seems to inhibit T cell activation and proliferation [58]. It is known that CD163
 6 is in charge of the uptake of the hemoglobin-haptoglobin complex [40] and ADAMTS13 [83]. In order to assess
- 6 is in charge of the uptake of the hemoglobin-haptoglobin complex [40] and ADAMTS13 [83]. In order to assess 7 whether α -syn could be a cognate for CD163, we did MST to assess co-interaction. For this, we used sCD163,
- 8 which constitutes almost the entire extracellular portion of the receptor and it has been previously approached for
- 9 similar questions [54]. Our analysis showed no interaction between the two proteins, thus suggesting α -syn is not
- 10 a direct ligand for CD163 (although a possible co-receptor interaction cannot be excluded). Thus, we investigated
- 11 whether sCD163 could have any other functional effect on myeloid cells that might be relevant in PD. The result
- 12 from our *in vitro* study on sCD163-associated α -syn-uptake suggests that sCD163 induces an increase in the
- 13 capacity of the monocytes and microglia cells to uptake extracellular α-syn. *In vitro*, NF-κB stimulation of T cells
- 14 induced internalization of sCD163, which then binds myosin [80] a molecule involved in phagocytosis [2].
- 15 Therefore, sCD163 might induce intracellular pathways that would influence the cellular response to α-syn.
- 16 Indeed, our data indicate that sCD163 required certain time to exert its effect on BV-2 cells, supporting induction
- 17 of certain cascades. Further investigation is required to fully understand the effects on α -syn uptake mediated by
- 18 this protein and its consequences in the myeloid response during PD.
- 19 In conclusion, our data show a PD-related increase in sCD163 in CSF and in serum (only in females), supporting
- 20 a role for monocytes in the immune response concomitant with the disease. The increase in sCD163 paralleled
- 21 those of accepted neuronal markers, therefore relating immune and neuronal events. Moreover, higher levels of
- 22 sCD163 were associated with poor cognitive scores, indicative of a relevant role for the monocytes and the immune
- 23 process in cognitive decline. The CSF-sCD163 increase was associated with immune biomarkers suggestive of a
- 24 permissive BBB and the activation of adaptive immunity. Moreover, our *in vitro* studies suggest that sCD163 may
- 25 have an effect on the capacity of the myeloid cells, such as monocytes and microglia, to uptake α -syn, further
- 26 indicative of a relevant role for the disease progression. Our work reveals sCD163 as a promising biomarker in
- 27 PD.
- 28

1 ACKNOWLEDGEMENTS

2 We acknowledge the invaluable technical help provided by Gitte Ulbjerg Toft (Department of Biomedicine,

- 3 Aarhus University); and by Helle Hauser Ryom (Department of Clinical Biochemistry, Aarhus University
- 4 Hospital). We are grateful to Prof Dr. Mart Saarma (Helsinki University), for his scientific support and Prof Poul
- 5 Henning Jensen (Aarhus University) for kindly providing the human α-syn protein. Samples were obtained from
- 6 the Neuro-Biobank of the University of Tuebingen, Germany (https://www.hih-tuebingen.de/en/about-
- 7 <u>us/core-facilities/biobank/</u>), which is supported by the local University, the Hertie Institute and the DZNE.
- 8

9 AUTHOR CONTRIBUTIONS

10 Concept development and designed the study: SKN, SAF, MRR. Performed experiments: SKN, SAF, DH.

- Analysed the data: SKN, SAF, KS, MRR. Drafted the manuscript: SKN, MRR. Coordinated sample selection and
 collected Biobank archive info: CS. Wrote jointly the final version of the manuscript: SAF, SKN, MRR. All
- 13 authors critically revised the manuscript and approved the final version.
- 14

15 FINANCIAL DISCLOSURE

- 16 The authors declare no conflict of interest. Funding support for the research covered on this article was provided
- 17 from the Michael J. Fox Foundation (MRR), the Bjarne Saxhof Fund administered through the Danish Parkinson's
- 18 Foundation (MRR), the Aarhus University Forskningsfond AU IDEAS center NEURODIN (MRR) and the Novo
- 19 Nordisk Foundation (DEO, NNF17OC0028806). SAF is funded by a PhD fellowship from the PhD School at the
- 20 Health Faculty, Aarhus University.
- 21
- 22

1 References

\mathbf{a}	
1	
4	

-		
3 4	1	Aflaki E, Moaven N, Borger DK, Lopez G, Westbroek W, Chae JJ, Marugan J, Patnaik S, Maniwang E, Gonzalez ANet al ₍ 2016 ₎ Lysosomal storage and impaired autophagy lead to
5		inflammasome activation in Gaucher macrophages. Aging Cell 15: $77_{-}88$ Doi
6		10.1111/acel.12409
7	2	Barger SR, Gauthier NC, Krendel M $_{ m (}2019$ $_{ m)}$ Squeezing in a Meal $_{ m :}$ Myosin Functions in
8		Phagocytosis. Trends Cell Biol: Doi 10.1016/j.tcb.2019.11.002
9	3	Beck AT, Steer RA, Ball R, Ranieri W $_{ m (}$ 1996 $_{ m)}$ Comparison of Beck Depression Inventories –
10		IA and _II in psychiatric outpatients. J Pers Assess 67: 588–597 Doi
11		10.1207/s15327752jpa6703_13
12 13	4	Bergeron D, Flynn K, Verret L, Poulin S, Bouchard RW, Bocti C, Fulop T, Lacombe G, Gauthier S, Nasreddine Zet al $_{ m (}2017$ $_{ m)}$ Multicenter Validation of an MMSE–MoCA
14		Conversion Table. J Am Geriatr Soc 65: 1067–1072 Doi 10.1111/jgs.14779
15	5	Bernatowicz P, Kowal K $_{(2016)}$ Soluble CD163 modulates cytokine production by
16 17		peripheral blood mononuclear cells stimulated by Dermatophagoides pteronyssinus allergens in vitro. Adv Med Sci 61: 249–254 Doi 10.1016/j.advms.2016.02.004
18	6	Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray–Berthat V, Bonduelle O,
19		Alvarez–Fischer D, Callebert J, Launay JMet al $_{ m (}2009_{ m)}$ Infiltration of CD4+ lymphocytes
20		into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J
21		Clin Invest 119: 182–192 Doi 36470 [pii] 10.1172/JCI36470
22	7	Brockmann K, Apel A, Schulte C, Schneiderhan–Marra N, Pont–Sunyer C, Vilas D, Ruiz–
23		Martinez J, Langkamp M, Corvol JC, Cormier Fet al $_{ m (}2016_{ m)}$ Inflammatory profile in
24		LRRK2_associated prodromal and clinical PD. J Neuroinflammation 13: 122 Doi
25		10.1186/s12974-016-0588-5
26	8	Brockmann K, Schulte C, Schneiderhan–Marra N, Apel A, Pont–Sunyer C, Vilas D, Ruiz–
27		Martinez J, Langkamp M, Corvol JC, Cormier Fet al (2017) Inflammatory profile
28		discriminates clinical subtypes in LRRK2_associated Parkinsons disease. Eur J Neurol 24:
29		427_e426 Doi 10.1111/ene.13223
30 31	9	Chahine LM, Qiang J, Ashbridge E, Minger J, Yearout D, Horn S, Colcher A, Hurtig HI, Lee VM, Van Deerlin VMet al ₍ 2013 ₎ Clinical and biochemical differences in patients having
32		Parkinson disease with vs without GBA mutations. JAMA Neurol 70: $852_{-}858$ Doi
33		10.1001/jamaneurol.2013.1274
34	10	Collins LM, Williams–Gray CH $_{ m (2016)}$ The Genetic Basis of Cognitive Impairment and
35		Dementia in Parkinsons Disease. Front Psychiatry 7: 89 Doi 10.3389/fpsyt.2016.00089
36	11	Davydova N, Harris NC, Roufail S, Paquet–Fifield S, Ishaq M, Streltsov VA, Williams SP,
37		Karnezis T, Stacker SA, Achen MG $_{ m (}2016$ $_{ m)}$ Differential Receptor Binding and Regulatory
38 39		Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor $_{\rm (}VEGF_{\rm)-}C$ and $_{\rm -}D.$ J Biol Chem 291: 27265–27278 Doi 10.1074/jbc.M116.736801
40 41	12	Dige A, Stoy S, Thomsen KL, Hvas CL, Agnholt J, Dahlerup JF, Moller HJ, Gronbaek H (2014) Soluble CD163, a specific macrophage activation marker, is decreased by anti–

1		TNF_alpha antibody treatment in active inflammatory bowel disease. Scand J Immunol
2	40	80: 417–423 Doi 10.1111/sji.12222
3 4	13	Edison P, Anmed I, Fan Z, Hinz R, Gelosa G, Ray Chaudhuri K, Walker Z, Turkneimer FE, Brooks DL 2013, Microglia, amyloid, and glucose metabolism in Parkinsons disease with
5		and without dementia Neuronsychopharmacology 38, 938, 949 Doi
6		10 1038/npp 2012 255
7	14	Etzerodt A. Maniecki MB. Moller K. Moller HI. Moestrup SK (2010), Tumor necrosis factor
8	11	alpha_converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the
9		scavenger receptor CD163. Journal of leukocyte biology 88: 1201–1205 Doj
10		10.1189/jlb.0410235
11	15	Etzerodt A. Moestrup SK (2013) CD163 and inflammation: biological, diagnostic, and
12		therapeutic aspects. Antioxidants & redox signaling 18: 2352–2363 Doi
13		10.1089/ars.2012.4834
14	16	Ferreira SA, Romero–Ramos M (2018) Microglia Response During Parkinsons Disease:
15		Alpha_Synuclein Intervention. Front Cell Neurosci 12: 247 Doi
16		10.3389/fncel.2018.00247
17	17	Folstein MF, Folstein SE, McHugh PR $_{ m (}1975_{ m)}$ "Mini–mental state". A practical method for
18		grading the cognitive state of patients for the clinician. J Psychiatr Res 12: $189{-}198$ Doi
19		0022_3956 ₍ 75 ₎ 90026_6[pii]
20	18	Galea J, Cruickshank G, Teeling JL, Boche D, Garland P, Perry VH, Galea I $_{ m (2012)}$ The
21		intrathecal CD163_haptoglobin_hemoglobin scavenging system in subarachnoid
22		hemorrhage. J Neurochem 121: 785–792 Doi 10.1111/j.1471–4159.2012.07716.x
23	19	Georgiev D, Hamberg K, Hariz M, Forsgren L, Hariz GM $_{ m (}$ 2017 $_{ m)}$ Gender differences in
24		Parkinsons disease: A clinical perspective. Acta Neurol Scand 136: $570_{-}584$ Doi
25		10.1111/ane.12796
26 27	20	Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati BB, Brooks DL (2006). In vivo imaging of microglial activation with [110] B
27		PK11195 PFT in idionathic Parkinsons disease Neurobiol Dis $21 \cdot 404 \cdot 412$
20	21	Goetz CG Poewe W Rascol O Samnajo C Stebbins GT Counsell C Giladi N Holloway RG
30		Moore CG, Wenning GKet al (2004) Movement Disorder Society Task Force report on the
31		Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19: 1020–1028
32		Doi 10.1002/mds.20213
33	22	Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez_Martin P, Poewe W,
34		Sampaio C, Stern MB, Dodel Ret al $_{(2008)}$ Movement Disorder Society–sponsored
35		revision of the Unified Parkinsons Disease Rating Scale $_{(}$ MDS $_{-}$ UPDRS $_{)}$: scale
36		presentation and clinimetric testing results. Mov Disord 23: $2129_{-}2170$ Doi
37		10.1002/mds.22340
38	23	Grozdanov V, Bliederhaeuser C, Ruf WP, Roth V, Fundel-Clemens K, Zondler L, Brenner D,
39		Martin–Villalba A, Hengerer B, Kassubek Jet al $_{ m (2014)}$ Inflammatory dysregulation of
40		blood monocytes in Parkinsons disease patients. Acta Neuropathol 128: $651_{-}663$ Doi
41		$10.1007/s00401_{-}014_{-}1345_{-}4$

1	24	Hall S, Janelidze S, Surova Y, Widner H, Zetterberg H, Hansson O (2018) Cerebrospinal
2		fluid concentrations of inflammatory markers in Parkinsons disease and atypical
3		parkinsonian disorders. Sci Rep 8: 13276 Doi 10.1038/s41598_018_31517_z
4	25	Harms AS, Delic V, Thome AD, Bryant N, Liu Z, Chandra S, Jurkuvenaite A, West AB (2017)
5		alpha_Synuclein fibrils recruit peripheral immune cells in the rat brain prior to
6		neurodegeneration. Acta Neuropathol Commun 5: 85 Doi 10.1186/s40478_017_0494_9
7 8	26	Hartl D, May P, Gu W, Mayhaus M, Pichler S, Spaniol C, Glaab E, Bobbili DR, Antony P, Koegelsberger Set al (2020) A rare loss_of_function variant of ADAM17 is associated
9		with late_onset familial Alzheimer disease. Mol Psychiatry 25: 629_639 Doi
10		10.1038/s41380-018-0091-8
11	27	Hemstedt TJ, Bengtson CP, Ramirez O, Oliveira AMM, Bading H (2017) Reciprocal
12		Interaction of Dendrite Geometry and Nuclear Calcium_VEGFD Signaling Gates Memory
13		Consolidation and Extinction. J Neurosci 37: 6946–6955 Doi 10.1523/JNEUROSCI.2345–
14		16.2017
15	28	Herlofson K, Heijnen CJ, Lange J, Alves G, Tysnes OB, Friedman JH, Fagundes CP $_{(}2018_{)}$
16		Inflammation and fatigue in early, untreated Parkinsons Disease. Acta Neurol Scand 138:
17		394_399 Doi 10.1111/ane.12977
18	29	Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, Weintraub D (2009) Validity of
19		the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease.
20		Neurology 73: 1738–1745 Doi 10.1212/WNL.0b013e3181c34b47
21	30	Hu X, Yang Y, Gong D $_{(}2017$ $_{)}$ Changes of cerebrospinal fluid Abeta42, t–tau, and p–tau in
22		Parkinsons disease patients with cognitive impairment relative to those with normal
23		cognition: a meta_analysis. Neurol Sci 38: 1953_1961 Doi 10.1007/s10072_017_3088_
24		1
25	31	Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y ₍ 2003 ₎
26		$Distribution \ of \ major \ histocompatibility \ complex \ class \ II-positive \ microglia \ and \ cytokine$
27		profile of Parkinsons disease brains. Acta Neuropathol (Berl):
28 29	32	Janelidze S, Lindqvist D, Francardo V, Hall S, Zetterberg H, Blennow K, Adler CH, Beach TG, Serrano GE, van Westen Det al ₍ 2015 ₎ Increased CSF biomarkers of angiogenesis in
30		Parkinson disease. Neurology 85: 1834–1842 Doi 10.1212/WNL.000000000002151
31	33	Jude C, Dejica D, Samasca G, Balacescu L, Balacescu O (2013) Soluble CD163 serum levels
32		are elevated and correlated with IL $_{-12}$ and CXCL10 in patients with long $_{-}$ standing
33		rheumatoid arthritis. Rheumatol Int 33: 1031–1037 Doi 10.1007/s00296–012–2459–4 $$
34	34	Kang JH, Irwin DJ, Chen–Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligorska T, Taylor
35		P, Pan S, Frasier Met al $_{(}2013_{)}$ Association of cerebrospinal fluid beta–amyloid 1–42, T–
36		tau, P_tau181, and alpha_synuclein levels with clinical features of drug_naive patients
37		with early Parkinson disease. JAMA Neurol 70: $1277_{-}1287$ Doi
38		10.1001/jamaneurol.2013.3861
39	35	Keren–Shaul H, Spinrad A, Weiner A, Matcovitch–Natan O, Dvir–Szternfeld R, Ulland TK,
40		David E, Baruch K, Lara–Astaiso D, Toth Bet al (2017) A Unique Microglia Type

1		Associated with Restricting Development of Alzheimers Disease. Cell 169: 1276 $$
2		1290.e1217 Doi 10.1016/j.cell.2017.05.018
3	36	King E, Thomas A $_{(2017)}$ Systemic Inflammation in Lewy Body Diseases: A Systematic
4		Review. Alzheimer Dis Assoc Disord 31: 346–356 Doi
5		10.1097/WAD.00000000000211
6	37	Klegeris A, Giasson BI, Zhang H, Maguire J, Pelech S, McGeer PL (2006) Alpha–synuclein
7		and its disease–causing mutants induce ICAM–1 and IL–6 in human astrocytes and
8		astrocytoma cells. FASEB J 20: 2000–2008 Doi 10.1096/fj.06–6183com
9	38	Klein SL, Flanagan KL (2016) Sex differences in immune responses. Nat Rev Immunol 16:
10		626–638 Doi 10.1038/nri.2016.90
11	39	Kosmopoulos M, Christofides A, Drekolias D, Zavras PD, Gargalionis AN, Piperi C (2018)
12		Critical Role of IL–8 Targeting in Gliomas. Curr Med Chem 25: 1954–1967 Doi
13		10.2174/0929867325666171129125712
14	40	Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK
15		(2001) Identification of the haemoglobin scavenger receptor. Nature 409: 198–201 Doi
16		10.1038/35051594
17	41	Kustrimovic N, Comi C, Magistrelli L, Rasini E, Legnaro M, Bombelli R, Aleksic I, Blandini F,
18		Minafra B, Riboldazzi Get al (2018) Parkinsons disease patients have a complex
19		phenotypic and functional Th1 bias: $cross$ -sectional studies of CD4+ Th1/Th2/T17 and
20		Treg in drug–naive and drug–treated patients. J Neuroinflammation 15: 205 Doi
21		$10.1186/s12974_018_1248_8$
22	42	Lawson C, Wolf S (2009) ICAM $_1$ signaling in endothelial cells. Pharmacol Rep 61: 22 $_32$
23	43	Lee SJ, Benveniste EN (1999) Adhesion molecule expression and regulation on cells of the
24		central nervous system. J Neuroimmunol 98: 77–88 Doi 10.1016/s0165–
25		5728 ₍ 99 ₎ 00084_3
26	44	Li YI, Wong G, Humphrey J, Raj T $_{(}2019$ $_{)}$ Prioritizing Parkinsons disease genes using
27		$population_scale\ transcriptomic\ data.\ Nat\ Commun\ 10:\ 994\ Doi\ 10.\ 1038/\ s41467_019_$
28		08912_9
29	45	Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, Quinn N, Sethi KD, Shults C,
30		Wenning GKet al (2003) Movement Disorders Society Scientific Issues Committee report:
31		SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov
32		Disord 18: 467–486 Doi 10.1002/mds.10459
33	46	Ma C, Panaccione R, Khanna R, Feagan BG, Jairath V $_{(2019)}$ IL12/23 or selective IL23
34		inhibition for the management of moderate_to_severe Crohns disease? Best Pract Res
35		Clin Gastroenterol 38–39: 101604 Doi 10.1016/j.bpg.2019.02.006
36 37	47	Madsen M, Moller HJ, Nielsen MJ, Jacobsen C, Graversen JH, van den Berg T, Moestrup SK (2004) Molecular characterization of the haptoglobin.hemoglobin receptor CD163.
38		Ligand binding properties of the scavenger receptor cysteine_rich domain region. J Biol
39		Chem 279: 51561–51567 Doi 10.1074/jbc.M409629200

1	48	Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, McGeer PL $_{(}2006)$ Role of ICAM $_{-}1$ in
2		persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol 197: 275-
3		283 Doi 10.1016/j.expneurol.2005.10.034
4	49	Mishra HK, Ma J, Walcheck B (2017) Ectodomain Shedding by ADAM17: Its Role in
5		Neutrophil Recruitment and the Impairment of This Process during Sepsis. Front Cell
6		Infect Microbiol 7: 138 Doi 10.3389/fcimb.2017.00138
7	50	Mollenhauer B, Zimmermann J, Sixel–Doring F, Focke NK, Wicke T, Ebentheuer J,
8		Schaumburg M, Lang E, Friede T, Trenkwalder Cet al (2019) Baseline predictors for
9		progression 4 years after Parkinsons disease diagnosis in the De Novo Parkinson Cohort
10		(DeNoPa). Mov Disord 34: 67–77 Doi 10.1002/mds.27492
11	51	Moller HJ $_{(}2012)$ Soluble CD163. Scand J Clin Lab Invest 72: 1–13 Doi
12		10.3109/00365513.2011.626868
13	52	Moller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK $_{ m (}$ 2004 $_{ m)}$ Plasma level of the
14		macrophage_derived soluble CD163 is increased and positively correlates with severity
15		in Gauchers disease. Eur J Haematol 72: 135–139 Doi 10.1046/j.0902–
16		4441.2003.00193.x
17	53	Moller HJ, Hald K, Moestrup SK $_{ m (}2002$ $_{ m)}$ Characterization of an enzyme_linked
18		immunosorbent assay for soluble CD163. Scand J Clin Lab Invest 62: 293–299
19	54	Moller HJ, Nielsen MJ, Maniecki MB, Madsen M, Moestrup SK (2010) Soluble
20		macrophage_derived CD163: a homogenous ectodomain protein with a dissociable
21		haptoglobin–hemoglobin binding. Immunobiology 215: 406–412 Doi
22		10.1016/j.imbio.2009.05.003
23	55	Moller HJ, Peterslund NA, Graversen JH, Moestrup SK $_{ m (}2002_{ m)}$ Identification of the
24		hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 99:
25		378_380 Doi 10.1182/blood.v99.1.378
26	56	Nissen SK, Shrivastava K, Schulte C, Otzen DE, Goldeck D, Berg D, Moller HJ, Maetzler W,
27		Romero–Ramos M $_{(2019)}$ Alterations in Blood Monocyte Functions in Parkinsons
28		Disease. Mov Disord 34: 1711–1721 Doi 10.1002/mds.27815
29	57	Nissen SK, Shrivastava K, Schulte C, Otzen DE, Goldeck D, Berg D, Moller HJ, Maetzler W,
30 21		Romero-Ramos M (2019) Alterations in Blood Monocyte Functions in Parkinsons
31 22	50	Disease. Mov Disord: Doi 10.1002/mds.27815
32 22	58	OCONNEIL GC, Tennant CS, Lucke–Wold N, Kabbani Y, Tarabisny AR, Chantler PD, Barr TL
22 24		(2017) Monocyte=lymphocyte cross=communication via soluble CD163 directly links
34 35		ischemic stroke. Sci Rep 7: 12940 Doi 10.1038/s41598_017_13291_6
36	59	Pan W, Wu X, He Y, Hsuchou H, Huang EY, Mishra PK, Kastin AJ (2013) Brain interleukin–
37		15 in neuroinflammation and behavior. Neurosci Biobehav Rev 37: 184–192 Doi
38		10.1016/j.neubiorev.2012.11.009
39	60	Patidar M, Yadav N, Dalai SK (2016) Interleukin 15: A key cytokine for immunotherapy.
40		Cytokine Growth Factor Rev 31: 49–59 Doi 10.1016/j.cytogfr.2016.06.001

1 2	61	Perner C, Perner F, Gaur N, Zimmermann S, Witte OW, Heidel FH, Grosskreutz J, Prell T ₍ 2019 ₎ Plasma VCAM1 levels correlate with disease severity in Parkinsons disease. J		
3		Neuroinflammation 16: 94 Doi 10.1186/s12974_019_1482_8		
4	62	Pey P, Pearce RK, Kalaitzakis ME, Griffin WS, Gentleman SM $_{ m (2014)}$ Phenotypic profil		
5		alternative activation marker CD163 is different in Alzheimers and Parkinsons disease.		
6		Acta Neuropathol Commun 2: 21 Doi 10.1186/2051_5960_2_21		
7	63	Polfliet MM, Fabriek BO, Daniels WP, Dijkstra CD, van den Berg TK $_{ m (}$ 2006 $_{ m)}$ The rat		
8		macrophage scavenger receptor CD163: expression, regulation and role in inflammatory		
9		mediator production. Immunobiology 211: 419–425 Doi 10.1016/j.imbio.2006.05.015		
10	64	Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y (2016) Aberrations in Peripheral Inflammatory		
11		Cytokine Levels in Parkinson Disease: A Systematic Review and Meta–analysis. JAMA		
12		Neurol 73: 1316–1324 Doi 10.1001/jamaneurol.2016.2742		
13 14	65	Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, Feng T, Lee M, Asinovski N, Frohlich Iet al (2014) Polarization of the effects of autoimmune and neurodegenerative		
15		risk alleles in leukocytes. Science 344: 519–523 Doi 10.1126/science.1249547		
16 17	66	Rocha NP, Scalzo PL, Barbosa IG, Souza MS, Morato IB, Vieira EL, Christo PP, Teixeira AL, Reis HJ (2014) Cognitive Status Correlates with CXCL10/IP–10 Levels in Parkinsons		
18		Disease. Parkinsons Dis 2014: 903796 Doi 10.1155/2014/903796		
19 20	67	Santaella A, Kuiperij HB, van Rumund A, Esselink RAJ, van Gool AJ, Bloem BR, Verbeek MM ₍ 2020 ₎ Inflammation biomarker discovery in Parkinsons disease and atypical		
21		parkinsonisms. BMC Neurol 20: 26 Doi 10.1186/s12883_020_1608_8		
22 23	68	Sawada H, Oeda T, Umemura A, Tomita S, Kohsaka M, Park K, Yamamoto K, Sugiyama H (2015) Baseline C–Reactive Protein Levels and Life Prognosis in Parkinson Disease. PLoS		
24		One 10: e0134118 Doi 10.1371/journal.pone.0134118		
25	69	Sawada M, Imamura K, Nagatsu T $_{ m (}2006$ $_{ m)}$ Role of cytokines in inflammatory process in		
26		Parkinsons disease. J Neural Transm Suppl: 373–381		
27	70	Scheller J, Chalaris A, Garbers C, Rose–John S $_{ m (}2011$ $_{ m)}$ ADAM17: a molecular switch to		
28		control inflammation and tissue regeneration. Trends Immunol 32: $380_{-}387$ Doi		
29		10.1016/j.it.2011.05.005		
30 31	71	Schlachetzki JCM, Prots I, Tao J, Chun HB, Saijo K, Gosselin D, Winner B, Glass CK, Winkler J $_{(2018)}$ A monocyte gene expression signature in the early clinical course of Parkinsons		
32		disease. Sci Rep 8: 10757 Doi 10.1038/s41598_018_28986_7		
33 34	72	Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A, Parkinson Study Group PI (2011) Serum urate and probability of dopaminergic deficit		
35		in early "Parkinsons disease". Mov Disord 26: 1864–1868 Doi 10.1002/mds.23741 $$		
36	73	Stacker SA, Achen MG $_{(2018)}$ Emerging Roles for VEGF–D in Human Disease.		
37		Biomolecules 8: Doi 10.3390/biom8010001		
38	74	Steiner O, Coisne C, Cecchelli R, Boscacci R, Deutsch U, Engelhardt B, Lyck R $_{(}2010$ $_{)}$		
39		Differential roles for endothelial ICAM $_1$, ICAM $_2$, and VCAM $_1$ in shear $_r$ esistant T cell		
40		arrest, polarization, and directed crawling on $blood_{-}brain barrier endothelium. $ J		
41		Immunol 185: 4846–4855 Doi 10.4049/jimmunol.0903732		

1	75	Stilund M, Reuschlein AK, Christensen T, Moller HJ, Rasmussen PV, Petersen T $_{ m (2014)}$
2 3		Soluble CD163 as a marker of macrophage activity in newly diagnosed patients with multiple sclerosis. PLoS One 9: e98588 Doi 10.1371/journal.pone.0098588
4	76	Stone KP, Kastin AJ, Pan W $_{(2011)}$ NFkB is an unexpected major mediator of interleukin–
5		15 signaling in cerebral endothelia. Cell Physiol Biochem 28: 115–124 Doi
6		10.1159/000331720
7	77	Storelli E, Cassina N, Rasini E, Marino F, Cosentino M (2019) Do Th17 Lymphocytes and
8		IL–17 Contribute to Parkinsons Disease? A Systematic Review of Available Evidence.
9		Front Neurol 10: 13 Doi 10.3389/fneur.2019.00013
10	78	Tansey MG, Romero–Ramos M (2019) Immune system responses in Parkinsons disease:
11		Early and dynamic. Eur J Neurosci 49: 364–383 Doi 10.1111/ejn.14290
12 13	79	Tentillier N, Etzerodt A, Olesen MN, Rizalar FS, Jacobsen J, Bender D, Moestrup SK, Romero_Ramos M (2016) Anti-Inflammatory Modulation of Microglia via CD163_
14		Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6–OHDA Parkinsons
15		Disease Model. J Neurosci 36: 9375–9390 Doi 10.1523/JNEUROSCI.1636–16.2016
16	80	Timmermann M, Buck F, Sorg C, Hogger P (2004) Interaction of soluble CD163 with
17		activated T lymphocytes involves its association with non-muscle myosin heavy chain
18		type A. Immunol Cell Biol 82: 479–487 Doi 10.1111/j.0818–9641.2004.01277.x
19	81	Tsakadze NL, Sithu SD, Sen U, English WR, Murphy G, DSouza SE (2006) Tumor necrosis
20		factor_alpha_converting enzyme (TACE/ADAM_17) mediates the ectodomain cleavage of
21		intercellular adhesion molecule_1 (ICAM_1). J Biol Chem 281: 3157–3164 Doi
22		10.1074/jbc.M510797200
23	82	Tysnes OB, Storstein A (2017) Epidemiology of Parkinsons disease. J Neural Transm
24		(Vienna) 124: 901–905 Doi 10.1007/s00702–017–1686–y
25 26	83	Verbij FC, Sorvillo N, Kaijen PHP, Hrdinova J, Peyron I, Fijnheer R, Ten Brinke A, Meijer AB, van Alphen FPJ, van den Berg TKet al (2017) The class I scavenger receptor CD163
27		promotes internalization of ADAMTS13 by macrophages. Blood Adv 1: 293–305 Doi
28		10.1182/bloodadvances.2016001321
29 30	84	Villa A, Gelosa P, Castiglioni L, Cimino M, Rizzi N, Pepe G, Lolli F, Marcello E, Sironi L, Vegeto Eet al ₍ 2018 ₎ Sex_Specific Features of Microglia from Adult Mice. Cell Rep 23:
31		3501_3511 Doi 10.1016/j.celrep.2018.05.048
32	85	Villumsen M, Aznar S, Pakkenberg B, Jess T, Brudek T (2019) Inflammatory bowel
33		disease increases the risk of Parkinsons disease: a Danish nationwide cohort study 1977-
34		2014. Gut 68: 18–24 Doi 10.1136/gutjnl-2017-315666
35	86	Wijeyekoon RS, Kronenberg–Versteeg D, Scott KM, Hayat S, Kuan WL, Evans JR, Breen DP,
36		Cummins G, Jones JL, Clatworthy MRet al (2020) Peripheral innate immune and bacterial
37		signals relate to clinical heterogeneity in Parkinsons disease. Brain Behav Immun $_{ m E}$ Doi
38		10.1016/j.bbi.2020.01.018
39	87	Xu S, Lu J, Shao A, Zhang JH, Zhang J $_{(2020)}$ Glial Cells: Role of the Immune Response in
40		Ischemic Stroke. Front Immunol 11: 294 Doi 10.3389/fimmu.2020.00294
41		

Cohort #1		PD	HC (CSF & serum)
Female/male	Mean	53/56	19/25
ns	Count	109	44
Age at onset	Mean ± SD	61.4 ± 10.7	-
	Min-Max, Count	[30-82], 109	-
Age at visit	Mean ± SD	66.6 ± 9.9	64.1± 10.7
ns	Min-Max, Count	[36-84], 109	[42-81], 44
Disease duration	Mean ± SD	5.2 ± 5.0	-
	Min-Max, Count	[0-22] 109	-
LEDD	Mean ± SD	351.9 ± 372.2	-
	Min-Max, Count	[0-1532], 106	-
Hoehn & Yahr	Mean ±S D	2,2 ± 0.8	-
	Min-Max, Count	[1-4], 105	-
UPDRS III	Mean ± SD	25.6 ± 10.6	-
	Min-Max, Count	[7-66], 96	-
MoCA	Mean ± SD	25.5 ± 4.9	26.9 ± 2.2
ns	Min-Max, Count	[11-30], 67	[23-30], 18
Mini Mental	Mean ± SD	27 ± 3.9	28 ± 3.1
ns	Min-Max, Count	[14-30], 100	[17-30], 30
MMSE (O+C)	Mean ± SD	27.1 ± 3.9	28 ± 3.1
ns	Min-Max, Count	[14-30], 105	[17-30], 30
CSF Abeta42	Mean ± SD	731 ± 266	902 ± 307 **
	Min-Max, Count	[118-1435] , 107	[352-1616], 39
CSF h-Tau	Mean ± SD	244 ± 172	273 ± 159
ns	Min-Max, Count	[25-1074], 107	[112-992], 39
CSF p-Tau	Mean ± SD	41± 19	50± 22 *
Min-Max, Count		[15-113], 103	[22-149], 39
CSF total α-syn	Mean ± SD	561 ± 281	496 ± 150
ns	Min-Max, Count	[190-1834], 92	[226-715], 18
Albumin CSF/serum x10 ⁻³	Mean ± SD	7,25 ± 3,8	6,64 ± 2,1
ns	Min-Max, Count	[2,10-20,58], 66	[2,72-11,69], 36

Т

Table 1 Detailed overview of cohort #1

Mean, standard derivation (SD), [range] and the number of individuals for whom the data were available at sampling time are shown for: L-dopa equivalent daily dose (LEDD), Unified Parkinson's Disease Rating Scale three (UPDRS III), the Montreal Cognitive Assessment (MoCA) score, the Mini-Mental State Examination (MMSE), MMSE original + converted from MoCA (MMSE O+C). Significance between groups was tested with unpaired t tests: p values with trends are stated, * p < 0.05, ** p < 0.05, * p < 0.05, 0.01.

.

Cohort #2		00	HC	НС
122 (148)		PD	(CSF & serum)	(incl. extra for serum X)
Female/male	Mean	45 / 61	11/5	20 / 22
	Count	106	16	42
Age at onset	Mean ± SD	59.1 ± 10.3	-	-
	Min-Max, Count	[38-76], 106	-	-
Age at visit	Mean ± SD	64.2 ± 10.7	56.9 ± 10.9 *	63.2 ± 11.5
	Min-Max, Count	[41-86],106	[43-77], 16	[42-81], 42
Disease duration	Mean ± SD	5.1 ± 3.5	-	-
	Min-Max, Count	[0-17], 106	-	-
LEDD	Mean ± SD	453.7 ± 335.6	-	-
	Min-Max, Count	[0-1574], 106	-	-
Hoehn and Yahr	Mean ± SD	2.0 ± 0.6	-	-
	Min-Max, Count	[1-4], 104	-	-
UPDRS III	Mean ± SD	22.8 ± 11.2	-	-
	Min-Max, Count	[3-66], 101	-	-
BDI II	Mean ± SD	8.3 ± 6.3	6.0 ± 1	6.8 ± 7.6
	Min-Max, Count	[0-27], 74	[5-7], 3	[0-22], 8
Sniffin sticks 12	Mean ± SD	6.7 ± 2.6	-	5
	Min-Max, Count	[2-12], 59	-	1
MoCA	Mean ± SD	25.8 ± 3.6	27.7 ± 4	27.0 ± 2.4
	Count	[11-30], 93	[23-30], 3	[23-30], 14
MMSE (O)	Mean ± SD	28.1 ± 2.3	28.3 ± 2.9	28.0 ± 3.4
	Min-Max, Count	[17-30], 89	[23-30], 6	[17-30], 24
MMSE (O+C)	Mean ± SD	28.1 ± 2.3	28.3 ± 2.9	28.0 ± 3.4
	Min-Max, Count	[17-30], 101	[23-30], 6	[17-30], 24
CSF Abeta42	Mean ± SD	701 ± 246.9	787 ± 248.3	-
	Min-Max, Count	[256-1312], 104	[352-1215], 16	-
CSF h-Tau	Mean ± SD	221.7 ± 109.5	233.8 ± 213.3	-
	Min-Max, Count	[57-737], 104	[129-992], 16	-
CSF p-Tau	Mean ± SD	38.6 ± 14.6	42.3 ± 29.7	-
	Min-Max, Count	[15-97], 103	[18-149], 1 <mark>6</mark>	-
CSF total α-syn	Mean ± SD	631 ± 274.7	531 ± 101.6	-
	Min-Max, Count	[200-1486], 71	[289-664], 13	-

Table 2 Detailed overview of cohort #2

Mean, standard derivation (SD), [range] and the number of individuals for whom the data were available at sampling time are shown for: L-dopa equivalent daily dose (LEDD), Unified Parkinson's Disease Rating Scale three (UPDRS III), Beck Depression Inventory II (BDI II), the Montreal Cognitive Assessment (MoCA) score, the Mini-Mental State Examination (MMSE) original score (O), MMSE original + converted from MoCA (MMSE O+C). \square : Extra 26 serum controls from cohort #1 were added, since measurements of nine cytokines were unaffected by an extra freezing/thaw cycle, for details see **Suppl. Table 1**. Significant differences were tested between PD and HC groups with unpaired t tests: * p 0.0124.



Figure 1 Overview of cohorts

Cross-sectional sampling of serum and CSF in two cohorts. Cohort #1 consists of a total of 153 individuals, 44 healthy controls (HCs) and 109 Parkinson's disease (PD) patients with early [<5 years since diagnosis] or late [\geq 5 years since diagnosis] stage disease. Treatment status of patients are shown in brackets; untreated (UT)/treated (T). More details of cohort #1 are found in **Table 1**. Cohort #2 consists of total 122 individuals, 16 HCs and 106 PD patients with early or late status. **\$**: Twenty-eight individuals from cohort #1 had new aliquots of the biological samples included and analyzed in cohort #2 (4 HC females (F), 4 F early PD (1UT/3T), 3 F late PD (1UT/2T), 10 male (M) early PD (7UT/3T), 7 M late PD (2UT/5T)). More details of cohort #2 are found in **Table 2 §**: Twenty-six serum samples from controls (9 F, 17 M) from cohort #1 were reused for in cohort #2 for analyzing nine cytokines, which were found insensitive for repeated thawing using 40-plex mesoscale. See **Suppl. Table 1** for an assay overview for cohort #2.







Soluble (s)CD163 levels in CSF A) and serum B) from healthy controls (HC) or Parkinson's disease (PD) patients at early (<5 years with diagnosis) or late (\geq 5 years with diagnosis) disease stage. Serum measurements were gender separated into female (F) and male (M) groups due to a priori identification of gender difference and include only treated patients. Data are mean \pm SD, values were log transformed to achieve normality. CSF scD163 for all PD patients were correlated to well characterized neurodegenerative/PD-CSF markers: C) alpha-synuclein (α -syn), D) total Tau (h-Tau), and E) phosphorylated Tau (p-Tau); as well as with clinical cognitive scores: F) the Montreal Cognitive Assessment (MoCA), G) the Mini-Mental State Exam (MMSE) original score (O), or H) original plus converted from MoCA (O+C). I) CSF α -syn, K) p-Tau and serum scD163 were correlated, and showed a similar trend for CSF levels of J) h-Tau. P values for one-way ANOVA with Tukey's multiple comparisons test values, respectively, Spearman two-tail p values (* <0.05, ** <0.01, ***<0.001, ***<0.0001), Spearman r, and best-fit slope with 95% confidences intervals are plotted. Further information on cognitive scoring correlations with respect to progression status and covariance can be found in Suppl. Table 2 &3.





Soluble (s)CD163 measurements in A) CSF and B) serum from healthy controls (HC) or Parkinson's disease (PD) patients with early (<5 years with diagnosis) or late (\geq 5 years with diagnosis) status, with serum measurements being gender separated into female (F) and male (M) groups due to a priori identification of gender difference and include only treated patients. Data are mean ±SD, values were log transform to achieve normality. CSF-sCD163 for all PD patients were correlated to well-characterized neurodegenerative/PD-CSF markers: C) alpha-synuclein (α -syn), D) total Tau (h-Tau), E) phosphorylated Tau (p-Tau), and F) Abeta42; as well as with clinical cognitive scores: G) the Montreal Cognitive Assessment (MoCA), H) the Mini-Mental State Exam (MMSE) original score (O), or I) original plus converted from MoCA (O+C). J) CSF α -syn, L) p-Tau and serum sCD163 were correlated, and showed a similar trend for CSF levels of K) h-Tau. No correlation was found for serum sCD163 and M) Abeta42 in CSF, P values for ordinary (parametric), or Kruskal-Wallis (non-parametric) one-way ANOVA with Tukey's or Dunn's multiple comparisons test values, respectively, Spearman two-tail p values (* <0.05, ** <0.01, ***<0.001, ****<0.0001), Spearman r, and best-fit slope with 95% confidences intervals are plotted. Further information on cognitive scoring correlations with respect to progression status and covariance can be found in Suppl. Table 4, 5 &6.



Figure 4 Screening of other CSF PD biomarkers (cohort #2)

Sixteen different CSF biomarkers from the 40-plex mesoscale assay had values >LLOD (lower limit of detection) and were tested for differences between healthy control (HC) and Parkinson's disease (PD) patient groups A-F); or with respect to progression from early (<5 years since diagnosis) to late (\geq 5 years since diagnosis) G-H); or with respect to treatment (T) status with or without (UT) L-dopa I-K). MCP-1 (CCL2) was gender separated due to a priori identification of gender difference I). Biomarkers with no differences (or no statistical trend) between groups are shown in Suppl. Fig 1. Data are mean \pm SD. P values are shown for unpaired (parametric) t test or (non-parametric) Mann-Whitney test; for (parametric) ordinary or (non-parametric) Kruskal-Wallis one-way ANOVA with Tukey's or Dunn's multiple comparisons test values, respectively, as appropriate: * <0.05, ** <0.01, ***<0.001, ****<0.0001. Lower limit of quantification (LLOQ).



Figure 5 Screening for additional serum biomarkers (cohort #2)

Twenty seven different serum biomarkers from the 40-plex mesoscale assay had values >LLOD (lower limit of detection) and were tested for differences between healthy control (HC) and Parkinson's disease (PD) patient groups A-F); or with respect to progression from early (<5 years since diagnosis) to late (\geq 5 years since diagnosis) G-H). IL-6 was gender separated due to a priori identification of gender difference E) Biomarkers with no differences between groups are shown in **Suppl. Figure 2**. Twenty-six extra/additional HCs serum samples from cohort #1 were added for biomarkers unaffected by extra freezing/thaw cycle (B,D,F,G). Data are mean ±SD. P values are shown for unpaired (parametric) t test or (non-parametric) Mann-Whitney test; for (parametric) ordinary or (non-parametric) Kruskal-Wallis one-way ANOVA with Tukey's or Dunn's multiple comparisons test values, respectively, as appropriate: *<0.05, **<0.01, ***<0.001, ***<0.0001. [1] one outlier from early PD was removed based on ROUT Q= 0.1%; if including the outlier: p=0.0523. Lower and upper limit of quantification (LLOQ and ULOQ).



Figure 6 Correlation of sCD163 and additional biomarkers (cohort #2)

A-B) CSF- and **C-D)** serum-sCD163 were compared to all 40-plex biomarkers with values above lower limed of detection (LLOD) measured in CSF (n=16) and serum (n= 27), respectively . **A&C**) Spearman p value, the green colour shows those with a p value below the Bonferroni adjusted threshold (p < 0.0031 for CSF and p < 0.0018 for serum) and **B&D**) r values are plotted as heat maps. Correlations are done for all Parkinson's disease (PD) patients or separated as late (\geq 5 years since diagnosis) or early (<5 years since diagnosis) PD status.





A-B) CSF biomarkers with values above lower limed of detection (LLOD) are correlated to Mini-Mental State Exam (MMSE) (original scores + converted from Montreal Cognitive Assessment (MoCA) (O+C)) and plotted as heat maps for **A**) Spearman p and **B**) r values. Correlations are done for all Parkinson's disease (PD) patients or separated as late (\geq 5 years since diagnosis) or early (<5 years since diagnosis) PD status. **C**) CSF IL-15 had the strongest correlation to MMSE O+C; plotted with the Spearman p and r [95% confidence interval (CI)] and the equation for the linear regression with a slope significantly different from 0. **D**) IL-15 was the only biomarker in serum with a significant correlation and linear regression to MMSE O+C. **E**) IL-15 in CSF had a strong correlation and linear regression to CSF-sCD163. **F**) VEGF-A measured in serum were the only biomarker (for both serum and CSF) with a significant correlation and linear regression to the Unified Parkinson's Disease Rating Scale three (UPDRS III) score. Spearman two-tail p values (* <0.05, ** <0.01, ***<0.001, ***<0.0001).



Figure 8 Serum, the goodness of fit from selected regression models Stepwise forward model strategies (**m1:** probability of entry is 0.1, probability of removal is 0.2; **m2:** probability of entry is 0.05, probability of removal is 0.1; **m3:** probability of entry is 0.1, probability of removal is 0.2, CD163 forced to be included) were used for a linear regression with robust variance component estimation for serum biomarkers with effect on PD progression scores: **A)** Unified Parkinson's Disease Rating Scale three (UPDRS III), **B)** Montreal Cognitive Assessment (MoCA), **C)** Mini Mental original score (MMSE O), or **D)** MMSE original score plus converted from MoCA (MMSE O+C). The models are compared using AIC and BIC and goodness of fit (R squared). The best models for each prediction score are plotted as fitted values versus measured values.



Figure 9 CSF, the goodness of fit from selected regression models Stepwise forward model strategies (**m1:** probability of entry is 0.1, probability of removal is 0.2; **m2:** probability of entry is 0.05, probability of removal is 0.1; **m3:** probability of entry is 0.1, probability of removal is 0.2, CD163 forced to be included) were used for a linear regression with robust variance component estimation for CSF biomarkers with effect on PD progression scores: **A)** Unified Parkinson's Disease Rating Scale three (UPDRS III), **B)** Montreal Cognitive Assessment (MoCA), **C)** Mini Mental original score (MMSE O), or **D)** MMSE original score plus converted from MoCA (MMSE O+C). The models are compared using AIC and BIC and goodness of fit (R squared). The best models for each prediction score are plotted as fitted values versus measured values.



Figure 10 sCD163 increases α -syn uptake in mouse BV-2 microglia and human THP-1 macrophage-like monocytes. A) Experimental design: BV-2 and THP-1 cells were incubated at three different conditions: 1. with iodine-labeled α -synuclein (¹²⁵I α -syn) (control); 2. Co-incubated with ¹²⁵I α -syn and sCD163 (5µg/mL) and 3. Pre-treated with sCD163 (5µg/mL) 30 min prior ¹²⁵I α -syn addition to the media. Cells were incubated for 5, 15, and 45 min after α -syn addition and collected for evaluation of α -syn internalization. Radioactive counts per minute (CPM) on THP-1 B) and BV-2 C) were normalized to α -syn average counts (treatment 1) and shown as % of control internalization. Statistics: Two-way ANOVA followed by posthoc Tukey's multiple comparison test when appropriate. P values different to control (α -syn alone) at the same time point: *<0.05 ****<0.0001; \$ different to all other treatments at the same time-point. \$\$\$\$ <0.0001; # different to adjacent time point in the same treatment: ## <0.01 #### <0.001 #### <0.0001; [##] difference to 5 min. Data is shown as mean ± standard error of mean (SEM). Figure done using Biorender.